IMiD-14 Gene Signature for Plasma Cell Resistance Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting resistance to immunomodulatory derivatives (IMiDs) in patients with plasma cell disorders, such as multiple myeloma, are inadequate due to unclear mechanisms of resistance and lack of specific prognostic markers.
Innovation Solution
Development of a gene expression profile signature (IMiD-14) that identifies patients as sensitive or resistant to IMiD treatment by measuring the normalized expression levels of prognosis-favorable and unfavorable genes, allowing for classification based on a pre-defined threshold.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If gene expression profiling is used to predict IMiD resistance, then prediction accuracy is improved, but measurement complexity increases
Solution Approach 1:
The gene expression profile is divided into two distinct sets: prognosis-favorable genes and prognosis-unfavorable genes. This segmentation allows for systematic measurement and comparison, where each set is evaluated separately and then integrated to produce the final IMiD-14 score, thereby managing measurement complexity through structured organization
Solution Approach 2:
The patent transforms complex gene expression data into a simplified one-dimensional IMiD-14 score by normalizing expression levels and calculating the difference between favorable and unfavorable gene sets. This dimensional reduction converts multi-gene complexity into a single predictive metric that maintains accuracy while reducing measurement complexity
2Reliability
If multiple gene expression levels are measured and normalized, then prediction reliability is improved, but processing time increases
Solution Approach 1:
The patent performs normalization of gene expression levels as a preliminary step before calculating the final score. By pre-processing the data to account for technical variations and establishing a standardized scale, the method ensures reliable comparisons across samples while streamlining the subsequent calculation process
Solution Approach 2:
The patent transforms raw gene expression levels into normalized values by changing the parameter scale. This parameter transformation allows for meaningful comparison between different genes and samples, improving prediction reliability while enabling efficient processing through standardized mathematical operations
Data Source
AI summary
The present invention provides methods for determining immunomodulatory derivatives (IMiDs) resistance in a subject having a plasma cell disorder.